A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cytokines stimulate Hodgkin lymphoma cells by recognizing JAK1-/JAK2-bound receptors. JAK blockade may thus be therapeutically beneficial in Hodgkin lymphoma. In this phase II study we assessed the safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Den Neste, Eric, André, Marc, Gastinne, Thomas, Stamatoullas, Aspasia, Haioun, Corinne, Belhabri, Amine, Reman, Oumedaly, Casasnovas, Olivier, Ghesquieres, Hervé, Verhoef, Gregor, Claessen, Marie-José, Poirel, Hélène A., Copin, Marie-Christine, Dubois, Romain, Vandenberghe, Peter, Stoian, Ioanna-Andrea, Cottereau, Anne S., Bailly, Sarah, Knoops, Laurent, Morschhauser, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927969/
https://www.ncbi.nlm.nih.gov/pubmed/29351986
http://dx.doi.org/10.3324/haematol.2017.180554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927969/
https://www.ncbi.nlm.nih.gov/pubmed/29351986
http://dx.doi.org/10.3324/haematol.2017.180554

Ejemplares similares